Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...
Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...
Keytruda succeeds n a Phase 3 trial for head and neck cancer, showing promising results for event-free survival, the study's ...
Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...
6d
Merck's Keytruda (pembrolizumab) met primary endpoint of event-free survival (EFS) in Phase 3 trial for newly diagnosed head ...
KEYTRUDA’s safety profile in this trial was found to be in line with previous studies, without any new safety concerns ...
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical ...
Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for increasing ...
Researchers sought to determine whether high antimetabolite dose intensity is related to higher treatment-induced toxicity in pediatric patients with ALL.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results